ClinicalTrials.gg
RecruitingNCT07610486OPTI-AmpUpdated Oct 5, 2026

Optimizing PreTerm Infant Ampicillin Dosing

A Phase 1/2 interventional study of Ampicillin prescribed by provider per standard of care for evaluation of early onset sepsis in Early Onset Sepsis, Preterm Neonates and NICU, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 0 Days to 7 Days. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Duke University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 5, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
0 Days to 7 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Sepsis by Duke University — 2 open to participants now, 3 under way, none of them phase 3. Sepsis · Duke University.

Planned enrollment
8th of 10
60 · median 375
Started
2026
the only one that year
Phase 1/2
Only one
of the 14
Registered
13th of 14
by date

Among the 14 studies in Sepsis by Duke University, this one is the 8th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 1/2, and was the 13th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

2 of the 14 studies in Sepsis by Duke University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 0 Days to 7 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Sepsis by Duke University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if preterm infants who are prescribed antibiotics shortly after birth can safely receive a shorter course of antibiotics (24 to 36 hours instead of 48 hours). The main questions it aims to answer are:

  • Does short-course ampicillin provide high enough levels of ampicillin at 48 hours?
  • Is short-course ampicillin safe for preterm infants to receive?

Preterm infants who are being prescribed ampicillin by their doctor and enroll in the study will stop ampicillin after a shorter than typical course, and researchers will collect blood samples to measure their ampicillin levels and follow them clinically to see how they do after receiving short-course ampicillin.

Participants will:

  • stop ampicillin earlier than 48 hours (between 24 to 36 hours, depending on how premature they are and the dosing of ampicillin their doctor has prescribed)
  • have one or more blood samples collected, including one around 48 hours from when they started ampicillin
  • have their data collected until 30 days after they receive short-course ampicillin, or until hospital discharge, whichever is sooner
Read the detailed description

OPTI-Amp is a prospective, open-label, non-randomized pharmacokinetic and safety trial of short-course ampicillin administered to preterm neonates in the Neonatal Intensive Care Unit (NICU) at Duke.

The objectives of the study are to 1) evaluate whether short-course ampicillin provides therapeutic exposures for 48 hours from ampicillin initiation for preterm neonates undergoing evaluation of early onset sepsis (EOS) and 2) evaluate the safety of short-course ampicillin compared to standard empiric ampicillin.

Approximately 60 neonates ≤34 weeks 6/7 days gestational age and \<7 days postnatal age at the time of screening, who are receiving empiric ampicillin prescribed per standard of care (SOC) by their treating provider will be enrolled in the study. Participants will be in the study up to 30 days or hospital discharge, whichever is sooner. Enrolled infants who receive short-course ampicillin will have a pharmacokinetic sample collected at 48 (+/-2) hours from the time that ampicillin was initiated. Additional opportunistic pharmacokinetic (PK) samples can be collected between the final ampicillin dose and 72 hours from ampicillin initiation if the patient is receiving other SOC labs; however, these are not required. Demographic information, clinical data, and biospecimen information (including date and time of sample collection) will also be collected for enrolled participants.

Opportunistic PK samples collection may begin immediately after consent is obtained. All enrolled infants will be in the safety population. Those with at least one PK sample will be included in the PK population. In addition to the risks of blood drawing and loss of confidentiality, there may be a risk of under treatment of EOS if clinical cultures result positive after ampicillin discontinuation and therapeutic exposure is not maintained between 24 or 36 hours until 48 hours. Participants that fall under the latter situation will either not be enrolled in the study or will be withdrawn as determined by the study PI.

03

Conditions studied

  • Early Onset Sepsis
  • Preterm Neonates
  • NICU
  • Ampicillin
  • Safety and Pharmacokinetics

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
0 Days to 7 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented from parent/guardian
  • Infants admitted to the Duke Neonatal Intensive Care Unit (NICU)
  • less than or equal to 34 6/7 weeks gestational age (GA) at birth and \< 7 days of life at time of screening
  • Prescribed ampicillin by provider per standard of care for evaluation of early onset sepsis

Exclusion criteria

Exclusion Criteria:

  • Infant on extracorporeal support (e.g., ECMO)
  • Positive blood culture or other confirmed infection
  • At time of consent, infants with GA \<28 0/7 weeks who have received more than 24 hours of empiric ampicillin OR infants with GA 28 0/7 to 34 6/7 weeks who have received > 32 to 36 hours of ampicillin, depending on dosing regimen
  • Has major congenital abnormalities where survival to 30 days of life is not expected
  • Receives a course of ampicillin that is longer (i.e., more doses) than the short-course defined regimen for their GA
  • Any condition which would make the participant, in the opinion of the investigator, unsuitable for the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Short-course Ampicillin

    Infants enrolled in the trial receive short-course empiric ampicillin (24 to 36 hours, depending on gestational age and prescribed dosing regimen), rather than a standard (48 hour) empiric ampicillin course

    Drug: Ampicillin prescribed by provider per standard of care for evaluation of early onset sepsis

Interventions

  • DrugAmpicillin prescribed by provider per standard of care for evaluation of early onset sepsis

    preterm infants receive less than 48 hours of prescribed ampicillin (i.e., a "short-course" ampicillin regimen) to provide the desired 48 hours of therapeutic exposures

06

What researchers measure

Primary outcomes

  1. Total plasma ampicillin concentration

    Total plasma ampicillin concentration at 48(+/-) 2 hours after ampicillin initiation, following a single gestational age defined short-course with no further ampicillin administration. Target attainment defined as total ampicillin concentration of ≥1 µg/mL. The short-course regimen is considered successful if target attainment is achieved in ≥90% of the overall study population.

    Time frame: data will be collected up to 50 hours from the first dose of ampicillin

Secondary outcomes

  1. Serious, unexpected, suspected adverse reactions to ampicillin

    Time frame: Data will be collected until 30 days from short-course ampicillin, or until hospital discharge

  2. Adverse events related to study procedures

    Time frame: Data will be collected until 30 days from short-course ampicillin, or until hospital discharge

  3. All-cause mortality at 30 days

    Time frame: Data will be collected until 30 days from short-course ampicillin, or until hospital discharge

  4. Antibiotic re-initiation within 7 days of short-course ampicillin

    Time frame: Data will be collected until 7 days from short-course ampicillin

  5. Culture-confirmed bacteremia within 7 days of short-course ampicillin

    Time frame: Data will be collected until 7 days from short-course ampicillin

  6. Necrotizing enterocolitis within 30 days of short-course ampicillin

    Time frame: Data will be collected until 30 days from short-course ampicillin, or until hospital discharge

07

Study locations

1 of 1 sites recruiting
  • Duke Health Neonatal Intensive Care Unit
    Durham, North Carolina 27705, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD collected for study purposes will be shared to the NICHD DASH data repository.

Supporting information: Study protocol, Informed consent form

Time frame: The IPD and supporting information will be available once data analysis is complete and will be available per NICHD DASH repository timelines.

Access criteria: Qualified researchers and scientists from academic, non-profit, and for-profit institutions can access data sent to NICHD DASH repository for secondary analysis. Access is controlled, requiring approval from the DASH Data Access Committee (DAC) after the investigator submits a research proposal, a data use agreement (DUA), and a study-specific Data Management and Sharing Plan.

Data sharing details ↗ · dash.nichd.nih.gov

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 28, 2026
StartActual
Jul 28, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Editedless than or equal to 34 completed6/7 weeks gestational age (GA) at birth and < 7 days of life at time of screening
Exclusion criteria
  • EditedAt time of consent, infants with GA <28 completed0/7 weeks who have received more than 24 hours of empiric ampicillin OR infants with GA 28 0/7 to 34 completed6/7 weeks who have received > 32 to 36 hours of ampicillin, depending on dosing regimen
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Editedless than or equal to 34 completed6/7 weeks gestational age (GA) at birth and < 7 days of life at time of screening
    Exclusion criteria
    • EditedAt time of consent, infants with GA <28 completed0/7 weeks who have received more than 24 hours of empiric ampicillin OR infants with GA 28 0/7 to 34 completed6/7 weeks who have received > 32 to 36 hours of ampicillin, depending on dosing regimen
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07610486
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
May 28, 2026
Start date
Jul 28, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Angelique Boutzoukas, MD, MPH
Contact
angelique.boutzoukas@duke.edu
919-668-4733

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion